Compare Mercadolibre Inc (MELI) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs 10X Genomics Inc — how do they compare? Mercadolibre Inc trades at $1,860.11 (market cap $94.13B), while 10X Genomics Inc trades at $78.99 (market cap $10.07B). The key difference: Mercadolibre Inc is far larger — about 9.3× 10X Genomics Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, 10X Genomics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 117 Days and 10X Genomics Inc for 92 Days on average.
| MELI | TXG | |
|---|---|---|
Market Cap | $94.13B | $10.07B |
Volume | 273,781 | 5,657,286 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $97.74 |
52-Week Low | $1.55K | $11.48 |
Typical Hold Time | 117 Days | 92 Days |
Enterprise Value | $101.77B | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,872.78, up 0.8% on the day, with a bullish technical signal and strong analyst consensus. Revenue growth remains robust, reaching $28.89 billion in 2025, though net income margins have softened. Recent news highlights expansion in Brazil, including one-hour delivery and pharmacy services, while the fintech ecosystem strengthens with a 75% surge in credit portfolio.
The outlook is positive given dominant market position and growth initiatives, but risks include macroeconomic headwinds in Latin America and elevated valuation multiples. Analyst price targets average $2,170, suggesting potential upside, supported by institutional buying interest.
10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.
TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
